Nov 3, 2026 · 9 min
Pfizer raises guidance as Apple and Palantir lose momentum
Pfizer Reports; Apple and Palantir Drop
The episode shows how earnings can produce sharply different market reactions when outlooks collide with product weakness, margin pressure, or slowing growth.
- 1Pfizer raised its full-year outlook, yet vaccine-revenue weakness still weighed on its shares.
- 2Apollo reported $1.06 trillion in assets under management as adjusted income declined and its flagship private-equity fund lost money.
- 3Apple flagged thinner margins, while Palantir fell on weaker guidance and signs of slowing growth.
Don't miss
The sharpest contrast comes from Pfizer raising its full-year outlook while its shares still weakened amid pneumococcal vaccine-revenue pressure.
The brief
Pfizer raised its full-year outlook, but shares weakened as pneumococcal vaccine revenue added pressure to an otherwise improved earnings picture.
Apollo reported $1.06 trillion in assets under management, yet adjusted net income declined and its flagship private-equity fund posted a quarterly loss.
Apple forecast strong holiday-season revenue growth but warned that higher component costs would thin margins, giving investors a less comfortable outlook.
Palantir’s decline reflected concern that growth is slowing and guidance is weakening, underscoring how quickly expectations can turn after earnings.
The Bloomberg Tech Minute shifts from markets to SpaceX, examining a demanding hiring process and the workplace culture shaped by Elon Musk.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.